Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A refined diagnostic algorithm for Bethlem myopathy.

D Hicks1, A K Lampe, R Barresi

  • 1Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, NE1 3BZ, Great Britain.

Neurology
|April 2, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

X-linked Emery-Dreifuss muscular dystrophy: a multicenter, Italian, cohort study.

Journal of neurology·2026
Same author

A consensus statement on a National Competency Framework for training and assessment of knowledge and skills in diabetes technologies, including hybrid closed loop (HCL), insulin pump systems, and continuous glucose monitoring (CGM) devices.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

The impact of the timing of pasta intake on sleep quality and health outcomes: a protocol for a randomized controlled trial.

Trials·2025
Same author

In response to Gulcin Akinci's and Haluk Topaloglu's letter regarding our article "Predictors of loss of ambulation in Duchenne muscular dystrophy: A systematic review and meta-analysis".

Journal of neuromuscular diseases·2025
Same author

Taking on the Titin: Muscle imaging as a diagnostic marker of biallelic <i>TTN-</i>related myopathy.

Journal of neuromuscular diseases·2025
Same author

Colorectal cancer patients-derived immunity-organoid platform unveils cancer-specific tissue markers associated with immunotherapy resistance.

Cell death & disease·2024
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
Same journal

Cerebral Artery Pulsatility, Premorbid Blood Pressure, and Small Vessel Disease on Brain Imaging: A Population-Based Study.

Neurology·2026
Same journal

Genetic Risk for Alzheimer Disease, Midlife Hypertension, and Dementia: The ARIC Neurocognitive Study.

Neurology·2026
Same journal

What is the Relevance of Neuron-Tumor Interactions in Malignant CNS Tumors?

Neurology·2026
See all related articles

Diagnosing Bethlem myopathy (BM) is challenging. Immunofluorescent labeling of collagen VI in skin fibroblasts offers a sensitive and specific method to detect COL6A mutations, aiding diagnosis.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biochemistry

Background:

  • Bethlem myopathy (BM) and Ullrich congenital muscular dystrophy (UCMD) result from mutations in collagen VI genes (COL6A1, COL6A2, COL6A3).
  • BM diagnosis is difficult due to overlapping clinical features and limitations of standard muscle biopsy immunohistochemistry.

Purpose of the Study:

  • To evaluate immunofluorescence (IF) techniques for diagnosing Bethlem myopathy.
  • To assess the utility of collagen VI IF in skin fibroblast cultures compared to muscle biopsy.

Main Methods:

  • Investigated dual immunofluorescence for collagen VI and perlecan in muscle tissue.
  • Analyzed collagen VI immunofluorescent labeling in skin fibroblast cultures from 40 patients.
  • Correlated IF findings with genetic testing results in blinded assessments.

Related Experiment Videos

Main Results:

  • Dual IF in muscle was not significantly different from controls in most BM patients.
  • Collagen VI IF in fibroblast cultures detected abnormalities in over 78% of genetically confirmed BM patients.
  • Prospective study showed fibroblast IF had 100% sensitivity and negative predictive value for COL6A mutations.

Conclusions:

  • Collagen VI immunofluorescent labeling in fibroblast cultures is a valuable diagnostic tool for Bethlem myopathy.
  • This method complements genetic testing, improving cost-effectiveness and efficiency in BM diagnosis.